KORRO BIO
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. In 2018,
KORRO BIO
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.korrobio.com
Total Employee:
51+
Status:
Active
Total Funding:
207.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Icosavax
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Obsidian Therapeutics
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sixty Degree Capital
Sixty Degree Capital investment in Series B - Korro Bio
Point72
Point72 investment in Series B - Korro Bio
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series B - Korro Bio
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Series B - Korro Bio
Surveyor Capital
Surveyor Capital investment in Series B - Korro Bio
Invus
Invus investment in Series B - Korro Bio
New Enterprise Associates
New Enterprise Associates investment in Series B - Korro Bio
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series B - Korro Bio
Verition Fund Management
Verition Fund Management investment in Series B - Korro Bio
Monashee Investment Management
Monashee Investment Management investment in Series B - Korro Bio
Official Site Inspections
http://www.korrobio.com Semrush global rank: 2.96 M Semrush visits lastest month: 5.49 K
- Host name: 23.185.0.3
- IP address: 23.185.0.3
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Korro Bio" on Search Engine
Korro Reports First Quarter 2024 Financial Results and …
3 days ago Net Loss: Korro’s net loss was $19.6 million for each of the three months ended March 31, 2024, and 2023. About Korro . Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform.See details»
Korro Bio and Frequency Therapeutics Announce Closing of …
Nov 3, 2023 Release Details. Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million. November 3, 2023. PDF Version. Korro will be focused on advancing a wholly owned portfolio of RNA editing programs. Post-transaction cash of approximately $170 million expected to fund operations into 2026.See details»
Korro Bio Announces Appointment of Tim Pearson to Board of …
CAMBRIDGE, Mass., October 25, 2023 – Korro Bio, Inc., a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both rare and highly prevalent diseases, announced on July 14, 2023, the proposed business combination with Frequency …See details»
Korro Reports First Quarter 2024 Financial Results and …
3 days ago CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...See details»
Korro Reports First Quarter 2024 Financial Results and
2 days ago CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), ... in drug development will play an integral role in shaping our clinical development strategy and strengthening our organization,” said Dr. Ram Aiyar, CEO and President of Korro. “Completion of our $70.0 million financing broadens our …See details»
2024-05-14 | NDAQ:KRRO | Press Release | Korro Bio Inc
3 days ago Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer. CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial …See details»
Press Releases – Korro Bio
Dec 7, 2023 Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline of RNA Editing Programs. January 5, 2022. Read more.See details»
Press Releases – Korro Bio, Inc.
Apr 1, 2024 CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen 44 th Annual Health Care Conference in Boston, Massachusetts, on Monday, March 4, 2024, at 2:10 p.m. February 27, 2024. Read More.See details»
Korro Bio Expands Leadership Team with Key Appointments
CAMBRIDGE, Mass., November 8, 2022— Korro Bio, Inc ., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Venkat Krishnamurthy, Ph.D., as Senior Vice President, Head of Platform and Stephanie Engels as Senior Vice President, Head of People and Culture.See details»
Governance Overview – Korro Bio, Inc.
Korro Bio, Inc. Learn more about Korro Bio, Inc.'s corporate governance and view the company's governance documents and committee charters.See details»
Korro Strengthens Leadership Team with Appointment of Shelby …
CAMBRIDGE, Mass., May 10, 2023 — Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel. In …See details»
Korro Bio, Inc. | LinkedIn
7,605 followers. 3w. Today, we announced a $70 million private placement led by Deep Track Capital with participation from other leading healthcare investors.See details»
Korro Bio and Frequency Therapeutics Announce Merger …
Jul 14, 2023 CAMBRIDGE & LEXINGTON, Mass., July 14, 2023--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Frequency Therapeutics,...See details»
Korro Announces $70 Million Private Placement - Yahoo Finance
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on...See details»
Korro Strengthens Leadership Team with Appointment of Shelby …
May 10, 2023 CAMBRIDGE, Mass.-- ( BUSINESS WIRE )--Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby...See details»
Korro Bio, Inc. (KRRO) - Yahoo Finance
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly...See details»
Korro Bio advances RNA editing candidate KRRO-110
3 days ago As Korro Bio, Inc. (NASDAQ:KRRO) forges ahead with its RNA-based therapeutic developments, the company's financial position and market performance are key indicators of its potential to sustain and capitalize on its scientific advancements. According to recent data from InvestingPro, Korro Bio holds a market capitalization of $464.1 …See details»
Release - Korro Bio
CAMBRIDGE, Mass., May 10, 2023 — Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the appointment of Shelby Walker, JD, as Senior Vice President and General Counsel. In this new role, Ms. Walker will lead Korro’s legal organization including Intellectual ...See details»
Korro Bio - Crunchbase Company Profile & Funding
About. Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms. Cambridge, Massachusetts, United States. 51-100. Series B. Private. www.korrobio.com. 5,207. Highlights. Acquisitions 1. Total Funding Amount. Unlock for free. Contacts 97. Employee Profiles 5.See details»
Korro Bio - Contacts, Employees, Board Members, Advisors
Organization. Korro Bio. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 5. Number of Board Member and Advisor Profiles 6. Contacts 97. About. Korro Bio has 5 current employee profiles, including Founder and Senior Vice President of Technology Andrew Fraley.See details»